Elimination of Leukemic Cells by the Combined Use of Ether Lipids in Vitro

Shinichiro Okamoto, Anita C. Olson

研究成果: Article

17 引用 (Scopus)

抄録

Two ether lipids, CP-46, 665-1 (4-aminomethyl-l-[2, 3-(di-n-decyloxy)-n-propyl]-4-phenylpiperidine) and ET-18-OCH3 (racemic 1-O-octadecyl-2-0-methylglycero-3-phosphocholine) have been shown to possess antileukemic activity in vitro. To explore the possible use of these compounds for purging remission bone marrow cells of leukemic cells, we examined the cytotoxic effect of these compounds on normal hematopoietic progenitor cells and leukemic cell line cells (HL-60, K-562, KG-la, KG-1, and Daudi) by using the clonogenic assay. When cells were treated with CP-46, 665-1 or ET-18-0CH3(50 μg/ml for 1 h), these compounds did not inhibit the growth of normal progenitors, whereas the growth of the clonogenic leukemic cells was inhibited with differences in their sensitivities to the cytotoxic effect of CP-46, 665-1 and ET-18-OCH3. Incubation of leukemic cells (HL-60 and Daudi cells) with both CP-46, 665-1 (50 μg/ml) and ET-18-OCH3 (50 Mg/ml) for 1 h resulted in a greater reduction of clonogenic leukemic cells than treated with each compound alone. Approximately a 3 log killing of clonogenic HL-60 cells and a 5 log killing of Daudi cells was achieved; however, the combined treatment of normal bone marrow cells with CP-46, 665-1 and ET-18-OCH3 did not alter the growth of normal progenitors. This combined treatment also selectively eliminated the leukemic cells (HL-60 and Daudi cells) from a mixture (1000:1) of normal bone marrow cells and leukemic cells. It is conceivable that the pronounced difference in sensitivity to this combined treatment can be exploited for the elimination of residual leukemic cells in autologous remission marrow grafts.

元の言語English
ページ(範囲)2599-2603
ページ数5
ジャーナルCancer Research
47
発行部数10
出版物ステータスPublished - 1987 5 15
外部発表Yes

Fingerprint

Ether
Lipids
HL-60 Cells
Bone Marrow Cells
Growth
In Vitro Techniques
Phosphorylcholine
Hematopoietic Stem Cells
Bone Marrow
CP 46665
Transplants
Cell Line
edelfosine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Elimination of Leukemic Cells by the Combined Use of Ether Lipids in Vitro. / Okamoto, Shinichiro; Olson, Anita C.

:: Cancer Research, 巻 47, 番号 10, 15.05.1987, p. 2599-2603.

研究成果: Article

@article{54d4a99a452e41c3b6ae7e2a9da255be,
title = "Elimination of Leukemic Cells by the Combined Use of Ether Lipids in Vitro",
abstract = "Two ether lipids, CP-46, 665-1 (4-aminomethyl-l-[2, 3-(di-n-decyloxy)-n-propyl]-4-phenylpiperidine) and ET-18-OCH3 (racemic 1-O-octadecyl-2-0-methylglycero-3-phosphocholine) have been shown to possess antileukemic activity in vitro. To explore the possible use of these compounds for purging remission bone marrow cells of leukemic cells, we examined the cytotoxic effect of these compounds on normal hematopoietic progenitor cells and leukemic cell line cells (HL-60, K-562, KG-la, KG-1, and Daudi) by using the clonogenic assay. When cells were treated with CP-46, 665-1 or ET-18-0CH3(50 μg/ml for 1 h), these compounds did not inhibit the growth of normal progenitors, whereas the growth of the clonogenic leukemic cells was inhibited with differences in their sensitivities to the cytotoxic effect of CP-46, 665-1 and ET-18-OCH3. Incubation of leukemic cells (HL-60 and Daudi cells) with both CP-46, 665-1 (50 μg/ml) and ET-18-OCH3 (50 Mg/ml) for 1 h resulted in a greater reduction of clonogenic leukemic cells than treated with each compound alone. Approximately a 3 log killing of clonogenic HL-60 cells and a 5 log killing of Daudi cells was achieved; however, the combined treatment of normal bone marrow cells with CP-46, 665-1 and ET-18-OCH3 did not alter the growth of normal progenitors. This combined treatment also selectively eliminated the leukemic cells (HL-60 and Daudi cells) from a mixture (1000:1) of normal bone marrow cells and leukemic cells. It is conceivable that the pronounced difference in sensitivity to this combined treatment can be exploited for the elimination of residual leukemic cells in autologous remission marrow grafts.",
author = "Shinichiro Okamoto and Olson, {Anita C.}",
year = "1987",
month = "5",
day = "15",
language = "English",
volume = "47",
pages = "2599--2603",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Elimination of Leukemic Cells by the Combined Use of Ether Lipids in Vitro

AU - Okamoto, Shinichiro

AU - Olson, Anita C.

PY - 1987/5/15

Y1 - 1987/5/15

N2 - Two ether lipids, CP-46, 665-1 (4-aminomethyl-l-[2, 3-(di-n-decyloxy)-n-propyl]-4-phenylpiperidine) and ET-18-OCH3 (racemic 1-O-octadecyl-2-0-methylglycero-3-phosphocholine) have been shown to possess antileukemic activity in vitro. To explore the possible use of these compounds for purging remission bone marrow cells of leukemic cells, we examined the cytotoxic effect of these compounds on normal hematopoietic progenitor cells and leukemic cell line cells (HL-60, K-562, KG-la, KG-1, and Daudi) by using the clonogenic assay. When cells were treated with CP-46, 665-1 or ET-18-0CH3(50 μg/ml for 1 h), these compounds did not inhibit the growth of normal progenitors, whereas the growth of the clonogenic leukemic cells was inhibited with differences in their sensitivities to the cytotoxic effect of CP-46, 665-1 and ET-18-OCH3. Incubation of leukemic cells (HL-60 and Daudi cells) with both CP-46, 665-1 (50 μg/ml) and ET-18-OCH3 (50 Mg/ml) for 1 h resulted in a greater reduction of clonogenic leukemic cells than treated with each compound alone. Approximately a 3 log killing of clonogenic HL-60 cells and a 5 log killing of Daudi cells was achieved; however, the combined treatment of normal bone marrow cells with CP-46, 665-1 and ET-18-OCH3 did not alter the growth of normal progenitors. This combined treatment also selectively eliminated the leukemic cells (HL-60 and Daudi cells) from a mixture (1000:1) of normal bone marrow cells and leukemic cells. It is conceivable that the pronounced difference in sensitivity to this combined treatment can be exploited for the elimination of residual leukemic cells in autologous remission marrow grafts.

AB - Two ether lipids, CP-46, 665-1 (4-aminomethyl-l-[2, 3-(di-n-decyloxy)-n-propyl]-4-phenylpiperidine) and ET-18-OCH3 (racemic 1-O-octadecyl-2-0-methylglycero-3-phosphocholine) have been shown to possess antileukemic activity in vitro. To explore the possible use of these compounds for purging remission bone marrow cells of leukemic cells, we examined the cytotoxic effect of these compounds on normal hematopoietic progenitor cells and leukemic cell line cells (HL-60, K-562, KG-la, KG-1, and Daudi) by using the clonogenic assay. When cells were treated with CP-46, 665-1 or ET-18-0CH3(50 μg/ml for 1 h), these compounds did not inhibit the growth of normal progenitors, whereas the growth of the clonogenic leukemic cells was inhibited with differences in their sensitivities to the cytotoxic effect of CP-46, 665-1 and ET-18-OCH3. Incubation of leukemic cells (HL-60 and Daudi cells) with both CP-46, 665-1 (50 μg/ml) and ET-18-OCH3 (50 Mg/ml) for 1 h resulted in a greater reduction of clonogenic leukemic cells than treated with each compound alone. Approximately a 3 log killing of clonogenic HL-60 cells and a 5 log killing of Daudi cells was achieved; however, the combined treatment of normal bone marrow cells with CP-46, 665-1 and ET-18-OCH3 did not alter the growth of normal progenitors. This combined treatment also selectively eliminated the leukemic cells (HL-60 and Daudi cells) from a mixture (1000:1) of normal bone marrow cells and leukemic cells. It is conceivable that the pronounced difference in sensitivity to this combined treatment can be exploited for the elimination of residual leukemic cells in autologous remission marrow grafts.

UR - http://www.scopus.com/inward/record.url?scp=0023179764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023179764&partnerID=8YFLogxK

M3 - Article

C2 - 3471316

AN - SCOPUS:0023179764

VL - 47

SP - 2599

EP - 2603

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -